HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Breast Cancer Update
00:00
Comparing PROTAC and oral SERD trial signals
Hamilton considers cross‑trial comparisons, efficacy and differing GI tolerability among oral SERDs and PROTACs.
Play episode from 16:28
Transcript
